Drug General Information
Drug ID
D03ZYQ
Former ID
DNCL003114
Drug Name
STX209
Drug Type
Small molecular drug
Indication Fragile X syndrome [ICD9: 332, 759.83; ICD10:F02.3, G20, Q99.2] Phase 3 [524095]
Company
Seaside Therapeutics
Formula
C10H12ClNO2
Canonical SMILES
C1=CC(=CC=C1C(CC(=O)O)CN)Cl
InChI
1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
InChIKey
KPYSYYIEGFHWSV-QMMMGPOBSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Gamma-aminobutyric acid B receptor Target Info Modulator [543621]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
GABAergic synapse
Estrogen signaling pathway
Morphine addiction
Reactome Activation of G protein gated Potassium channels
G alpha (i) signalling events
Class C/3 (Metabotropic glutamate/pheromone receptors)
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
WikiPathways GPCRs, Class C Metabotropic glutamate, pheromone
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
Potassium Channels
GPCR ligand binding
GPCR downstream signaling
References
Ref 524095ClinicalTrials.gov (NCT01706523) Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders. U.S. National Institutes of Health.
Ref 543621(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.